Bergenbio ASA is a biopharmaceutical company specializing in the research and development of pharmaceuticals, with a focus on first-generation AXL inhibitors. The company targets the treatment of aggressive diseases, especially advanced and treatment-resistant cancers. Bergenbio is in clinical phase and has developed a pipeline of promising drugs, including BEMCENTINIB.
The company collaborates with Oncoinvent ASA to promote innovation in cancer treatment, which underlines their commitment to the development of effective treatments. Bergenbio ASA is also committed to environmental, social and governance (ESG) responsibility, and actively works with investor relations by providing regular updates and reports to its investors.